Kabra Drugs gets Chhattisgarh LOI for ₹200 Cr pharma plant

Kabra Drugs Limited has received a Letter of Intent (LOI) from the Government of Chhattisgarh to establish a pharmaceutical manufacturing facility at Nava Raipur Pharma Park. The project entails a proposed investment of approximately ₹200 Crore and is expected to generate 250 direct and indirect employment opportunities. This strategic initiative aims to expand the company's manufacturing capacity and support its long-term growth strategy, subject to the execution of definitive agreements and necessary approvals.

The LOI, received on 12 June 2026, outlines the establishment of a facility dedicated to pharmaceutical and related healthcare manufacturing activities. The company stated that the project is expected to enhance its manufacturing footprint and boost revenue multifold. However, the realization of these benefits is contingent upon implementation timelines and the receipt of regulatory sanctions.

Project Details and Conditions

The proposed investment is subject to applicable State Government policies, approvals, and sanction orders. The disclosure notes that incentives are roughly 60% on date, though final figures depend on compliance with statutory requirements. The company emphasized that the investment will proceed only after fulfilling all necessary conditions.

Particulars	Details
Name of the Authority	Government of Chhattisgarh
Date of receipt of communication	12 June 2026
Proposed investment	Approximately ₹200 Crore
Location	Nava Raipur Pharma Park, Chhattisgarh
Expected employment generation	Approximately 250 direct and indirect opportunities

Forward-Looking Statements

The company cautioned that certain statements in the disclosure are forward-looking and involve risks and uncertainties. Actual results may differ materially due to factors such as changes in government policies, regulatory approvals, market conditions, and project implementation timelines. Kabra Drugs undertakes no obligation to publicly update these statements except as required by law.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+8.21%	+1.13%	-13.41%	-18.92%	+89.93%	+341.71%

Kabra Drugs Limited shareholders have approved a change in the company's name and the alteration of its object clause. The resolutions were passed through a postal ballot conducted via remote e-voting, concluding on June 10, 2026. These approvals allow the company to rebrand and expand its operational objectives as outlined in its Memorandum of Association.

The postal ballot process was conducted in accordance with Sections 108 and 110 of the Companies Act, 2013, and relevant rules. The notice for the ballot was dated May 8, 2026, and the remote e-voting facility was provided by CDSL. The voting period commenced on May 12, 2026, and concluded on June 10, 2026.

Voting Results

The scrutinizer, CS Jay Arvind Jain of Jay Jain & Associates, verified the votes cast by shareholders. A total of 35 members participated, casting 2,750,027 valid votes. The results showed strong support for both special resolutions.

Resolution 1: Change in Name

Particulars	Number of Members Voted	Number of valid votes cast	% of total valid votes
In favor	34	2,746,027	99.85
In against	1	4,000	0.15
Total	35	2,750,027	100.00

Resolution 2: Alteration of Object Clause

Particulars	Number of Members Voted	Number of valid votes cast	% of total valid votes
In favor	34	2,746,027	99.85
In against	1	4,000	0.15
Total	35	2,750,027	100.00

The resolutions were deemed passed on June 10, 2026, with the requisite majority. The company will now proceed with the necessary regulatory steps to implement the name change and the alteration of the object clause.